medigraphic.com

2006, Número 2

<< Anterior Siguiente >>

Arch Cardiol Mex 2006; 76 (2)


Estado actual del trasplante cardíaco en Nuevo León: Primeros 33 casos

Herrera GE, Molina GJ, Decanini AH, Ibarra FM, Torres GM, Macías HC, González OR, de la Fuente MFJ, Elizondo SLA, Villarreal AMA, Ortega DO, Martínez BP, García CA, Becerra GO, Martínez RD, Contreras LC, Olivares CMC, Treviño TA

Idioma: Español
Referencias bibliográficas: 30
Paginas: 151-162
Archivo PDF: 138.69 Kb.


RESUMEN

La insuficiencia cardíaca se ha constituido como una de las principales causas de muerte en nuestra comunidad. El trasplante cardíaco se ha erigido como la última alternativa eficaz cuando el manejo médico y quirúrgico de la insuficiencia cardíaca han sido agotados, brindando al paciente tasas de sobrevida del 80% a un año. Desafortunadamente, la evolución de un paciente trasplantado de corazón puede acompañarse de complicaciones como rechazo del injerto o infecciones secundarias al uso de inmunosupresores. En el presente artículo reportamos la experiencia adquirida con 33 casos. Nuestro programa ha alcanzado logros importantes como trasplantar con éxito no sólo a pacientes de edad avanzada, sino por primera vez en América Latina a pacientes asistidos de manera ambulatoria con el Sistema Thoratec TLC II. A pesar de las condiciones económicas limitadas que prevalecen en nuestro país y de haber enfrentado las mismas complicaciones que el resto de los programas a nivel mundial, en los enfermos tratados, la sobrevida es del 82% a un año, cifra similar a la reportada en la literatura.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. ROGER VI, WESTON SA, REDFIELD MM: Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344–50.

  2. BARNARD CN: The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital. Cape Town. S Afr Med J 1967; 41: 1271-1274.

  3. AZIZ S, BIEBER CP, REITZ BA, BIEBER MM, OYER PE, HOIT G, ET AL: Preparation and efficacy of Cyclosporin-A liposomes for prolongation of cardiac allograft survival. Transplant Proc 1981; 13(1 Pt 1): 410-411.

  4. OSADA N, CHAITMAN BR, DONOHUE TJ, WOLFORD TL, STELKEN AM, MILLER LW: Long term cardiopulmonary exercise performance after heart transplantation. Am J Cardiol 1997; 79: 451-456.

  5. TAYLOR DO, EDWARDS LB, MOHACSI PJ, BOUCEK MM, TRULOCK EP, KECK BM, ET AL: The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J Heart Lung Transplant 2003; 22: 616–624.

  6. KESLER KA, HANOSH JJ, O´DONNELL J, FAUST S, TURRENTINE MW, MAHOMED Y, ET AL: Heart transplantation in patients with Marfan´s syndrome: a survey of attitudes and results. J Heart Lung Transplant 1994; 13(5): 899-904.

  7. BLANCHE C, BLANCHE DA, KEARNEY B, SANDHU M, CZER LS, KAMLOT A, ET AL: Heart transplantation in patients seventy years of age and older: A comparative analysis of outcome. J Thorac Cardiovasc Surg 2001; 121(3): 434-435.

  8. HERRERA GE, NOON GP, DURAND JB, STETSON SJ, ZYLICS S, JOHNSON L, ET AL: Trasplante cardíaco heterotópico: Experiencia de trece años en el Hospital Metodista del Colegio de Medicina de Baylor. Arch Inst Cardiol Mex 1999; 69: 526-533.

  9. ROSE EA, GELIJNS AC, MOSKOWITZ AJ, HEITJAN DF, STEVENSON LW, DEMBITSKY W, ET AL: Long term use of a left ventricular assist device for end stage heart failure. N Engl J Med 2001; 345: 1435-1443.

  10. FARRAR DJ, BUCK KE, COULTER JH, KUPA EJ: Portable pneumatic biventricular driver for the Thoratec ventricular assist device. ASAIO Journal 1997; 43: M631-M634.

  11. LINDENFELD JA, MILLER GG, SHAKAR SF, ZOLTY R, LOWES BD, WOLFEL EE, ET AL: Drug therapy in the heart transplant recipient: Part I: Cardiac rejection and immunosuppressive drugs. Circulation 2004; 110(24): 3734-3740.

  12. MICHAELS PJ, ESPEJO ML, KOBASHIGAWA J, ALEJOS JC, BURCH C, TAKEMOTO S, ET AL: Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58–69.

  13. SLOTA M, GREEN M, FARLEY A, JANOSKY J, CARCILLO J: The role of gown and glove isolation in the reduction of nosocomial infection in children with solid organ transplantation. Critical Care Medicine 2001; 29(2): 405-412.

  14. LENNER R, PADILLA M, TEIRSTEIN A, GASS A, SCHILERO G: Pulmonary complications in cardiac transplant recipients. Chest 2001; 120(2): 508-513.

  15. GROSSI P, FARINA C, FIOCCHI R, DALLA GASPERINA D: Prevalence and outcome of invasive fungal infections in 1963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70(1): 112-116.

  16. ANTRETTER H, HOFER D, KLAUS A, LARCHER C, MARGREITER J, MARGREITER R: Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention. Dtsch Med Wochenschr 2000; 125(15): 445-451.

  17. GRADEK WQ, D´AMICO C, SMITH AL, VEGA D, BOOK WM: Routine surveillance endomyocardial biopsy continues to detect significant rejection late after heart transplantation. J Heart Lung Transplant 2001; 20(5): 497-502.

  18. BALK AH, ZONDERVAN PE, VAN DER MEER P, VAN GELDER T, MOCHTAR B, SIMOONS ML, ET AL: Effect of adopting a new histological grading system of acute rejection after heart transplantation. Heart 1997; 78(6): 603-607.

  19. MICHAELS PJ, ESPEJO ML, KOBASHIGAWA J, ALEJOS JC, BURCH C, TAKEMOTO S, ET AL: Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58–69.

  20. WAGNER FM, REICHENSPURNER H, UBERFUHR P, WEISS M, FINGERLE V, REICHART B: Toxoplasmosis after heart transplantation: diagnosis by endomyocardial biopsy. J Heart Lung Transplant 1994; 13(5): 916-918.

  21. KEOGH A: Long-term Benefits of Mycophenolate Mofetil after Heart Transplantation. Transplantation 2005; 79(3): S45-S46.

  22. MIDTVEDT K, FAUCHALD P, LIEN B, HARTMANN A, ALBRECHTSEN D, BJERKELY BL, ET AL: Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin Transplant 2003; 17: 69–74.

  23. KNOOP C, ANTOINE M, VACHIERY JL, DEPRE G, ALONSOVEGA C, STRUELENS M, ET AL: Gastric perforation due to mucormycosis after heart-lung and heart transplantation. Transplantation 1998; 66(7): 932-935.

  24. HALLORAN PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.

  25. CASTRO P, ARRIAGADA G, MORENO M, MORAN S, BECKER P, ZALAQUETT R, ET AL: Humoral rejection in heart transplantation. Report of 2 cases. Rev Med Chil 2000; 128(11): 1245-1249.

  26. MEISER BRUNO, REICHART BRUNO, ADAMIDIS IOANNIS, UBERFUHR PETER, KACZMAREK INGO: First experience with de novo Calcineurin-Inhibitor-Free Immunosuppression Following Cardiac Transplantation. American Journal of Transplantation 2005; 5(4): 827-831.

  27. KEOGH A, RICHARDSON M, MEROULA B, RUYGROK P, SPRATT P, GALBRAITH, ET AL: Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110(17): 2694-2700.

  28. SOUZA GS, GARCIA-GALLONT R, MAIREN JA, VILLACA SS, GONTIJO RC, VIOTTI EA, ET AL: Sirolimus and Micophenolate Mofetil: A reliable drug combination to prevent acute rejection and to protect graft function after renal transplantation. A retrospective analysis of 1 year’s follow up in adult kidneyrecipients. Transplantation 2004; 78(2): 269-270.

  29. STRAATMAN LP, COLES JG: Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 2000; 70(3): 541-3.

  30. KAVANAUGH T, YACOUB MH, KENEDY J, AUSTIN PC: Return to work after heart transplantation: 12 year follow up. J Heart Lung Transplant 1999; 18(9): 846-851.




2020     |     www.medigraphic.com